|Home | About | Journals | Submit | Contact Us | Français|
Establishing botanical extracts as globally-accepted polychemical medicines and a new paradigm for disease treatment, requires the development of high-level quality control metrics. Based on comprehensive chemical and biological fingerprints correlated with pharmacology, we propose a general approach called PhytomicsQC to botanical quality control.
Incorporating the state-of-the-art analytical methodologies, PhytomicsQC was employed in this study and included the use of liquid chromatography/mass spectrometry (LC/MS) for chemical characterization and chemical fingerprinting, differential cellular gene expression for bioresponse fingerprinting and animal pharmacology for in vivo validation. A statistical pattern comparison method, Phytomics Similarity Index (PSI), based on intensities and intensity ratios, was used to determine the similarity of the chemical and bioresponse fingerprints among different manufactured batches.
Eighteen batch samples of Huangqin Tang (HQT) and its pharmaceutical grade version (PHY906) were analyzed using the PhytomicsQC platform analysis. Comparative analysis of the batch samples with a clinically tested standardized batch obtained values of PSI similarity between 0.67 and 0.99.
With rigorous quality control using analytically sensitive and comprehensive chemical and biological fingerprinting, botanical formulations manufactured under standardized manufacturing protocols can produce highly consistent batches of products.
Quality control for herbal extracts containing tens to hundreds of characteristic phytochemicals pose a challenge for developing robust quality control metrics [1,2]. Variations in climatic conditions, geographic locations, methods of harvest, processing and extraction contribute to differences in the composition of the final product. Quality of herbal formulations was mainly assessed by highly skilled herbalists using sensory analyses including smell, taste and texture. More recently, these organoleptic methods have been augmented by histological identification , plant genetics [4,5] and increasingly sophisticated chemical analyses such as thin layer chromatography (TLC), gas chromatography (GC) , capillary electrophoresis  and liquid chromatography (LC) and detection methods such as UV/VIS absorption , Raman spectroscopy , infrared absorption , evaporative light scattering and mass spectrometry (MS) [11-14]. A typical certificate of analysis for an herbal formulation contains organoleptic information, TLC markers, specifications for water content, water and alcohol soluble extractives, total and acid soluble ash content, heavy metal analysis, microbial test, pesticide analysis and marker compound analysis as illustrated in a batch of PHY906 (Table (Table1).1). While these data are useful and generally accepted for herbal dietary supplements, they do not fully characterize the phytochemical composition or the biological response of the herbal extract.
While the current standards for quality controls utilizes absolute quantitation of a few specific chemical marker compounds , there is increasing interest in using complete fingerprint patterns to characterize more completely the multi-chemical species . However, no single analytical chemical method has high enough sensitivity and resolution to detect every potential phytochemical class of molecules.. Thus, an orthogonal biological methodology would be a useful complementary QC metric requirement. A robust bioresponse fingerprint incorporating living cells as the biological 'detector' and the resulting genomic differential display profile [16,17] after exposure to the botanical extract could provide a sensitive and global biological metric that may help validate batch-to-batch similarity and establish quality standards.
PhytomicsQC is a methodology combining chemical analysis, bioresponse analysis and animal pharmacology to determine batch-to-batch reproducibility (Figure (Figure1).1). Thus, it is a unified platform integrating: (1) information-rich chemical and bioresponse fingerprints, (2) molecular resolution details, (3) robust technologies (4) quantitative data, and (5) statistical pattern comparisons. For chemical analysis and fingerprinting, LC/MS was chosen for its sensitivity, broad capability and spectral sensitivity. Differential gene expression was selected for bioresponse fingerprinting (PCT US99/24851) for its comprehensive response, biological sensitivity and standardized methodology.
Huangqin Tang (HQT) is a classical Chinese medicine formula for treating gastrointestinal ailments including diarrhea, nausea and abdominal cramps . PHY906 is a modified pharmaceutical preparation of HQT (US Patent No. 7,025,993). PHY906 reduces gastrointestinal toxicity and enhances the anti-tumor efficacy of some anti-cancer drugs in animal models [19-21] and is currently under clinical investigations [22-24].
The present study aims to describe and exemplify the PhytomicsQC approach to the quality control of herbal formulae using the example of HQT and its pharmaceutical derivative PHY906.
A total of 18 batches of HQT were included in the present study. Four batches coded as PHY906-6, 7, 8, 10 were manufactured with PhytoCeutica's proprietary SOP. Eight batches of HQT were purchased from Sun Ten Pharmaceutical Co. LTD in Taiwan and designated as HQT-E, F, G, H, I, J, K and L. Six batches of HQT were obtained from various vendors (Chung Song Zong, Ko Da, Min Tong, Sheng Chang, Sheng Foong, Kaiser; Taiwan) who did not provide quality information, and were labeled as HQT-CSZ, KD, MT, SC, SF and KP3. The proprietary standard operating procedures (SOP) by PhytoCeutica for PHY906 used hot water extraction (80°C) of four herbs, namely Scutellaria baicalensis Georgi (S), Paeonia lactiflora Pall. (P), Glycyrrhiza uralensis Fisch. (G) and Ziziphus jujuba Mill. (Z) (ratio 3:2:2:2). The hot water extraction is then spray dried with insoluble dextran into a granulated powder, packaged and stored in foil containers at 4°C.
Chemical standards including baicalin (S), baicalein (S), wogonin (S), scutellarin (S), glycyrrhizin (G), ononin (G), liquiritin (G), liqiritigenin (G), paeoniflorin (P) and albiflorin (P), were obtained from Chromadex (USA). Apigenin and formic acid were obtained from Sigma-Aldrich (USA). Solvents were of LC/MS grade from JT Baker (USA).
Dried PHY906 or HQT powder (100 mg) was dissolved in one mL of 80°C water. The mixture was vortexed for one minute, placed in an 80°C water bath for 30 additional minutes with one minute of vortexing for every ten minutes. The sample was then cooled in a water bath of ambient temperature for five minutes, centrifuged for ten minutes at 10,000 rpm (Eppendorf Model 5810R, USA) and the resulting supernatant was filter (0.2 μm) sterilized. For subsequent LC/MS analysis, a 20 μL aliquot of this light brown extract was diluted with 980 μL of water. The final nominal concentration after extraction and dilution was 2 mg of dry weight PHY906 or HQT powder extract per mL of water. For biological experiments, the 100 mg/mL nominal concentration solution stock was diluted in the appropriate buffer or medium to the required final concentration.
High-performance liquid chromatography (HPLC) was performed with a Waters (USA) CapLC XE Pump equipped with a CapLC autosampler and a Waters (USA) CapLC 2996 Photodiode Array Detector. The eluents were (A) 100% water with 0.1% formic acid and (B) 100% acetonitrile with 0.1% formic acid and the column was a Waters Atlantis dC18 3 μm 0.3 mm × 150 mm NanoEase column (USA). The column was heated to 40°C and was preceded by a 0.5 μm precolumn frit. Gradient elution from 0 to 50% B over 70 minutes at 8 μL/min was used with an initial hold of five minutes. The column was then ramped to 95% B over four minutes, held in place for two minutes and returned to initial conditions over two minutes. Total run time was 120 minutes. Electrospray ionization was performed on a Micromass (UK) Q-Tof-II mass spectrometer. Samples (0.5 μL) were introduced without splitting into the electrospray interface through a 60 μm stainless steel capillary tube. A positive capillary voltage of 3.25 kV was used in positive ion mode and a negative capillary voltage of 3.25 kV was used in negative ion mode. The electrospray source was heated to 80°C and the desolvation gas (N2) was heated to 150°C at a flow rate of 400 L/hr. The Q-Tof was scanned from 50-2000 amu over one second. The resolution of the instrument under these conditions was ~10,000. For exact mass measurements, a reserpine lock mass ([M+H] of 609 amu) was introduced at the electrospray interface allowing mass measurements to be within 0.0002 amu. With external standards, mass accuracy to 0.002 amu was routine with experimental and theoretical mass matching accuracy of 20 ppm or better.
Three cell lines, namely Jurkat (ATCC no TIB-152), KB (ATCC no CCL-17) and HepG2 (ATCC no HB-8065), were selected for the experiments. HepG2 was selected for three reasons: (1) the cell line is stable, robust and well characterized; (2) the number of differentially expressed genes in HepG2 is generally observed to be higher than in the other two cell lines and (3) the liver is considered the primary drug-metabolizing organ for oral drugs. The HepG2 hepatocellular carcinoma cell line was cloned and a cell-bank created. A strict set of SOPs were developed to ensure reproducible growth characteristics including passage number and cell density. A HepG2 sub-clone cell was thawed with three passages to 80% confluency in 10% FBS complete MEME media at 37°C with 5% CO2. Computed IC50 values (concentration required to inhibit cell growth by 50%) were based on three independent experiments comparing a 72-hour exposure of the cells to eight concentrations ranging from 0.001 to 10 mg/mL of the PHY906-6 extract with control untreated cells. Cells were stained with 0.5% methylene blue, lysed with 1% sarcosine and cell viability determined by UV/VIS absorbance at A595.
Three independent experiments were performed on the HepG2 cells treated with one IC50 dose of the herbal extract or control buffer for 24 hours. At this time point, 100% of the cells were still viable. RNA was collected for gene profiling. GeneChip hybridization experiments with Affymetrix Human genome chip U133A (USA) were carried out at the Affymetrix Resource Laboratory, Yale University School of Medicine, USA. Data were processed with Microarray Suite 5.0 (Affymetrix, USA) software to generate a list of candidate genes for further investigation.
Selected gene probes were purchased as Assays-on-Demand from Applied Biosystems (USA) to confirm and quantify the candidate genes identified in the GeneChip experiments.
PHY906-6, 7, and 8 and HQT-F were compared for their effectiveness in potentiating the antitumor activity of the cancer chemotherapy drug CPT-11 or Camptosar® (Pfizer, USA). Female BDF-1 mice (Charles River Laboratories, USA) of 4-6 weeks old (16-20 grams) implanted with murine Colon 38 colorectal cancer cells (National Cancer Institute, USA) were used in the experiments. Colon 38 cells were grown in RPMI 1640 medium (JRH Biosciences, USA) supplemented with 10% fetal bovine serum and 100 μg/ml kanamycin. Cells were maintained at 37°C in a humidified atmosphere of 5% CO2:95% air. For studies of the effects of PHY906 on antitumor efficacy and toxicity, Colon 38 cells (1-2 × 106 cells in 0.1 ml phosphate-buffered saline, PBS) were transplanted subcutaneously (sc) into the BDF-1 mice. The length and width of the tumors were measured with a sliding caliper. The tumor size (S) was estimated according to the formula as follows:
where L is length, W is width.
After 10 to 14 days, mice with tumor sizes of 150-300 mm3 were selected. Treatment groups consisted of five mice each. Tumor size, body weight and mortality of the mice were monitored daily. Mice were sacrificed when the tumor size reached 10% of the body weight.
PHY906 was administered per oral (po) whereas Camptosar® was administered intraperitoneally (ip). PHY906 was given twice daily (bid) at approximately 10 am and 3 pm. On days when Camptosar® was also administered, PHY906 was given 30 minutes earlier. Unless otherwise indicated, dosages were 500 mg/kg for PHY906 and 360 mg/kg for Camptosar®. Mice in the control groups were administered a vehicle of either PBS (ip) or water (po). All animal studies were conducted at the Yale University Animal Facility and approved by the Institutional Animal Care and Use Committee.
The linear correlation R value is a standard statistical method  used to compare two datasets and to compare the absolute intensity or value of each of the collected (N) data points. These data points can be either ion current spectral intensities collected by LC/MS, UV-VIS or relative gene expression level values determined by qRT-PCR. The R value varies between -1.0 (perfect anti-correlation) and 1.0 (perfect correlation) and is a measure of the similarity of the two sets of intensities. The Phytomics Similarity Index (PSI) is also a statistical method that compares the fingerprint patterns by computing a correlation value not of the intensities of the N peaks but rather on the ratio data computed for each of the N data points with each of the other (N-1) data points. Using these (N-1) ratio values in the computation for each of the N data points provides the similarity of that peak in relation to all of the other peaks in the fingerprint pattern (PCT US02/34121) The ratio information is incorporated into the analysis as it provides relative information between various peak intensities reflecting the importance of the balance of the compound amounts (or gene expression levels). As an example, the integrated ion counts for each of the N peaks (mass and retention time) are extracted from the overall spectra of two different batches (A and B). These N ion intensities, representing the chemical fingerprint of each batch, are placed, conceptually, along the diagonal of a matrix of dimension N × N and the ratios of the intensities are placed in the assigned Mi,j (i ≠ j and i, j ≤ N) off-diagonal matrix locations. There are, therefore, a total of N(N-1)/2 unique non-diagonal elements describing the full set of intensity ratio information between all of the peaks with each peak contributing (n-1) ratios. Matrices A and B were respectively designated as MA and MB. Each column/row in MA and MB may be represented by the vectors as follows:
The linear correlation is then computed using all of the columns or rows in both matrices.
The correlation value R for each column i.e. peak, can be obtained with the standard Pearson coefficient or the Spearman ranked coefficient . The result of this analysis is a vector of R scores, where each vector element corresponds to a data point (e.g. MS peak, or gene) that is common to both datasets. While each data point (i) has its own correlation score, Ri, the average of all of the individual R scores produces a diagnostic single value for similarity defined as the PSI. In this example, the PSI score would range between 0.0 (complete dissimilarity) to 1.0 (complete identity) to -1.0 (perfect anti-correlation). The individual PSI values can be weighted by a variety of factors including intensity, slope or biological importance. A weighting function found to be valuable is the individual peak slope calculated from plotting (n-1) ratios for peak i batch A to the equivalent (n-1) ratios for peak i in batch B. Highly similar batches tend to have PSI values greater than 0.85 with only a few outliers at lower PSI values. Batches that have poor similarity tend to have PSI values less than 0.75 with a greater number of individual outliers at lower PSI values. The PSI algorithm along with tools for filtering and sorting the LC/MS data were implemented in the software package PhytomicsQC™.
Multiple extractions of PHY906 exhibited similar LC/MS profiles and indicated an extraction efficiency of 85% with a composition greater than 80% low molecular weight (<1000 amu) phytochemical species. (Figure (Figure2)2) The high extraction efficiency and the similarity of the phytochemical profiles from multiple extractions suggested that the soluble sample was an excellent representation of the phytochemical components.
Comparison of LC/UV-VIS spectra and positive (+) and negative (-) ion mode LC/MS spectra of PHY906 (Figure (Figure3)3) indicated the presence of a similar pattern of peaks with various intensity profiles. LC-MS (+) detected 39 distinct and quantifiable peaks suitable for use in a chemical fingerprint. In contrast, LC-MS(-) revealed 32 of the 39 peaks found in positive-ion mode and no additional new peaks whereas UV/VIS detection revealed only 22 of the 39 peaks directly and no additional peaks.
A freshly prepared extract of PHY906 was analyzed by LC/MS (+) and indicated no significant changes over a period of at least 18 hours (Figure (Figure4).4). Samples stored at -80°C were stable for a period of at least one month at a concentration of 100 mg/mL.
A total of 64 LC/MS peaks were detectable in PHY906-6  under current LC/MS conditions. A diagnostic chemical fingerprint pattern of 39 of the LC/MS (+) peaks was chosen for quality control. The peaks selected for the chemical fingerprint all had peak intensities greater than 0.2%, reproducible peak integration in three independent spectra and linearity over a ten-fold concentration range. Each of the 39 peaks identified in the PHY906 LC/MS (+) spectrum was unique to an individual herbal component; 25 from (S), 3 from (P), 10 from (G) and 1 from (Z) (Figure (Figure5).5). These 39 peaks represented 77% of the total ion count (TIC), summed over the overall chromatogram from 0 to 65 minutes, at a threshold of 1%, 82% of the TIC at a threshold of 1.5% and 87% of the TIC at a threshold of 2.0%. A list of these 39 phytochemical peaks is in Additional file 1.
Quantitative analysis was performed for six markers from (S), two markers from (G) and two markers from (P). No relevant marker from (Z) was available although one definitive marker peak is identified with mass 159.085 amu. Recovery studies reported a range between 96% and 105%. Standard curves for all markers were linear in the range 0.1 to 20 mg/ml with linear correlation R-values greater than 0.99. The ten marker standards accounted for approximately 20% of the total mass of PHY906, 38% of the total mass of phytochemicals after correction for excipient and residual water content and 58% of the total mass of phytochemicals excluding excipient, residual water content and simple sugars (See Additional file 1).
Ten of the 39 peaks were identified and confirmed with external marker standards, high-resolution MS and MS/MS fragmentation. An additional 13 of 39 peaks were tentatively identified with high-resolution MS and/or MS/MS. These 23 peaks comprised 78% of the ion current intensity by all 39 peaks. The majority of these identified compounds were flavonoids (60%), saponins and triterpenoids.
Of the approximately 18,000 genes monitored, only 100-300 genes were significantly regulated as indicated by an over 1.5 fold change in the differential gene expression level in HepG2 cell culture in the presence of a one IC50 dose of an herbal extract over a period of 24 hours. This list of genes was further filtered by reproducible qRT-PCR and comparative gene function analysis to form a unique signature set of 15-20 genes (Figure (Figure66).
Gene response expression data observed at an exposure of one IC50 concentration of eight herbs resulted in a composite bioresponse gene set of 524 genes at a minimum cut-off of 1.7 fold change in expression level (Figure (Figure7).7). Unique gene expression patterns are evident for each herb or herbal formulation. A biochemical pathway analysis of these 524 genes suggested that over 50% of the genes were either in signaling pathways or involved in cellular metabolism. This gene-list represented an objective biological quality control metric for an herbal extract.
In the specific case of PHY906-6, three independent experiments revealed 1172, 1846 and 1158 regulated genes in HepG2 cells, of which 466 genes were common in all three experiments. Subsequent filtering of regulated genes with changes of 1.5 fold, 2.0 or 3.0 folds with respect to untreated control resulted in a surprisingly small common gene set of 261, 77 or 28 genes respectively. The set of 77 genes was filtered to a subset of 17 genes, 15 of which were confirmed by qRT-PCR analysis. Nearly all (14/15) of the altered genes were up-regulated. The full expression range for these 15 genes varied from 3-fold down-regulated to over-400-fold up-regulated (Table (Table2).2). The subset of 15 genes formed a unique bioresponse signature of the PHY906 extract as a quality control metric for quantitative batch-to-batch comparisons.
The PSI method was tested and validated with artificial data sets created within the boundary conditions of typical experimental data. Two identical datasets produced a PSI value of 1.0. Random data sets provided low PSI values in the range of 0.0 to 0.1. Data values greater than ten provided a robust and stable score whereas five or fewer data points did not provide reliable results. PSI was accurate when the variations between the two datasets were spread over a majority of the data values. If only one of the data points was variable, both the PSI average and the R-value correlation were high. However, the data point was easily identified in the PSI histogram plot as a low value outlier.
The 39 peak chemical fingerprints were used to compare 17 batches of PHY906 and generic forms of HQT with a clinical standard batch PHY906-6. Mass spectra of all batches revealed subtle (but distinct) quantitative differences in the peak intensity pattern. With the extracted intensities for each of the 39 chemical fingerprints, we computed the PSI and conventional correlation values to compare similarity (Table (Table3).3). PSI values ranged from 0.67 to 0.99 whereas the correlation R values tightly clustered between 0.97 and 0.99. PSI values of 0.99 confirmed that the 39 peak chemical fingerprints of PHY906-6, 7 and 8 that were manufactured as sequential batches using the same ingredient herbs are nearly identical as chemical fingerprint patterns of two sequential LC/MS data sets of the same sample would have a PSI of 0.99. PHY906-10 was also found to be highly similar (PSI 0.97) to PHY906-6 although it was manufactured with herbs harvested six years later (group I). Similarly, the seven batches of group II manufactured by the same vendor as group I were also highly consistent with each other (PSI 0.95-0.98) but differed from the clinical batch PHY906-6 (PSI 0.0.81-0.94). The greatest variation, however, was between PHY906-6 and the six batches in group III (PSI 0.67-0.96) sourced from various vendors. Some batches such as HQT-SC, HQT-KP3 and HQT-KD were very similar to PHY906-6 with PSI scores greater than 0.90 while other batches such as HQT-MT and HQT-SF were significantly different with PSI scores less than 0.75. Without vendor information for these samples, it was impossible to determine product batch-to-batch reproducibility.
Although a very modest correlation (R2 = 0.81) existed between PSI values and R values, the small range of R values could not be used definitively to discriminate between various batches of HQT. The PSI was apparently more sensitive to variations in the intensity pattern because each of the n peaks had (n-1) ratios used in defining the correlation coefficient with the corresponding peak in a separate batch while in the standard R value each peak intensity only contributed 1/n to the overall correlation coefficient.
Three clinical batches PHY906-6, 7 and 8 and two non-clinical batches HQT-E and F were selected for bioresponse fingerprint analysis as they were all manufactured by a single vendor with batch HQT-E exhibiting the highest chemical fingerprint similarity (PSI = 0.94) and HQT-F the lowest chemical fingerprint similarity (PSI = 0.81) compared with PHY906-6. Bioresponse PSI values computed with qRT-PCR data of the 15 gene expression pattern were 0.99 for PHY906-7, 0.98 for PHY906-8, 0.94 for HQT-E and 0.68 for HQT-F compared with PHY906-6 (Table (Table4).4). This complementary bioresponse fingerprints confirmed the rank-order similarity observed in the chemical fingerprints.
Based on chemical and bioresponse analysis, three batches (PHY906-6, PHY906-10 and HQT-F) all produced by the same manufacturer, were used to investigate the effects on the anti-tumor activity of Camptosar® against murine colorectal cancer in mice (Figure (Figure8).8). There was a significant efficacy enhancement for Camptosar® by batch PHY906-6 and batch PHY906-10 (P = 0.0001) but no significant enhancement by batch HQT-F (P = 0.386) as determined by the paired t-test. These in vivo results were consistent with the similarity ranking in both in vitro chemical and bioresponse fingerprints.
The challenge of assessing the consistency of different batches of a botanical extract is inherent in the phytochemical complexity of botanical extracts. This challenge is made more formidable due to the fact that two batches of a botanical extract with the same chemical spectrum may have different biological activities if the bioactive chemical species is not detectable by the specific chemical analysis methodologies. Similarly, two batches of a botanical extract with different chemical fingerprint compositions may exhibit the same biological activity if the phytochemicals responsible for the difference are biologically inert. This challenge demands comprehensive quality control of polychemical botanical extracts to include multiplexed and orthogonal methods for both chemical and biological characterization.
While the traditional chemical analysis of standard marker compounds provides a useful quantitative mass balance, patterns of information-rich chemical fingerprints provide a complementary, powerful and practical approach to herbal quality control. Well suited for the analysis of the phytochemical-rich extract of PHY906, LC-MS offers excellent sensitivity, molecular resolution and good reproducibility in providing a comprehensive chemical fingerprint pattern. Other information-rich analytical chemical methods such as LC-NMR, UV-VIS and FT-IR are also useful. However, while these methods are well suited for the characterization of low molecular weight, phytochemical-rich botanical extracts, these chemical analysis may not be well suited to fully characterize the complex and heterogeneous protein/carbohydrate profiles often associated with important herbal or fungal extracts. A complementary biological methodology is required.
Comprehensive biological methodologies such as a quantifiable and global bioresponse fingerprinting are more advantageous than a few specific single enzyme/receptor assays. The advantages are due primarily to the inherent multi-factorial biological activities of botanical extracts. Even in the absence of a complete understanding of the exact bioactive chemical species and the underlying mechanisms of action, the global fingerprints provide a comprehensive and objective assessment of an herbal extract according to quality control metrics. As illustrated by the example of PHY906, the results indicate that a sensitive cellular detector and a gene expression readout is a useful approach to characterizing an integrated bioresponse of macromolecule-rich extracts found in various fungal extracts. Examination of multiple cell types as potential "detectors" revealed that these complex polychemical mixtures only regulate a few hundreds of genes out of a total of ~18,000 possible genes. This list of a few hundred genes could be filtered down to a smaller subset of genes to form a selective, unique and quantifiable bioresponse signature pattern. Interestingly, we found no obvious similarity in the gene expression bioresponse pattern for any of the individual herbal ingredients used in the manufacture of PHY906 as compared with the complete PHY906 formulation. This finding suggests that the bioresponse of PHY906 mixture, is more complex than the simple summation of the individual bioresponses of the ingredients.
The ability to manufacture consistent batches of herbal extracts is fundamental to evidence-based scientific and clinical study of botanical extracts. The problems of botanical extract consistency [27-29] are mainly due to poor product manufacturing protocols or non-standard manufacturing procedures. The results of this study of eighteen different batches of HQT confirm that significant differences could be observed from samples from different vendors. However, the analysis also strongly indicates that when careful sourcing of botanical ingredients and standardized manufacturing protocols are employed, that multiple batches of a complex botanical formulation, produced in different years and with different harvests of raw herbal ingredients, can also be highly consistent. The present study suggests that herbal batches with chemical fingerprint PSI similarity scores greater than 0.85 are likely to be pharmacologically bioequivalent.
Chemical fingerprints and bioresponse fingerprints corroborated by an in vivo pharmacology model, provide orthogonal and complementary characterization methodologies for determining batch-to-batch similarity. Both LC/MS and qRT-PCR are standardized, highly reproducible and cost-effective for characterizing pharmaceutical botanical extracts. While neither methodology by itself is sufficient to characterize a botanical extract, the combination of chemical and biological characterization does provide information-rich, high resolution metrics for comparing different batches of an herbal extract.
PhytomicsQC will be continually improved. The next generation of the PhytomicsQC platform will include sophisticated data mining tools and multiplexed chemical and biological response fingerprints to identify the biologically active subset of the chemical fingerprints and utilize PSI values that combine chemical and biological information..
PhytomicsQC is a first generation platform for botanical quality control that integrates high resolution, global chemical fingerprints, novel bioresponse genomic expression fingerprints, in vivo validation and a statistical pattern comparison algorithm, to provide an information-rich approach to determining the batch-to-batch similarity of botanical extracts. When this comprehensive methodology was used to analyze HQT and its pharmaceutical derivative PHY906, some significant differences were found between herbal batches from different manufacturers. However, when herbal selection and manufacturing are carefully controlled, batches manufactured years apart could be highly similar in their chemical, cellular response and pharmacological profiles.
S: Scutellaria baicalensis Georgi; P: Paeonia lactiflora Pall; G: Glycyrrhiza uralensis Fisch; Z: Ziziphus jujuba Mill; QC: Quality Control; HQT: Huangqin Tang; po: per oral or by mouth; ip: intraperitoneally; bid: "bis in die"; Latin for twice a day; PSI: Phytomics Similarity Index; UV-VIS: Ultraviolet-Visible; MS: Mass Spectrometry; LC/MS (+) (-): Liquid Chromatography coupled Mass Spectrometry (positive mode) (negative mode); TIC: Total Ion Current; HPLC: High Pressure Liquid Chromatography; GC:Gas Chromatography; TLC: Thin Layer Chromatography; IACUC: Institutional Animal Care and Use Committee; PSI: Phytomics Similarity Index
The authors of this paper are associated with PhytoCeutica, Inc.; YCC is the scientific founder and the other authors are or were employees of PhytoCeutica, Inc. RT, SHL and YCC hold stock or stock options in the company.
RT developed the PSI methodology. AP and JG conducted the LC/MS characterization of HQT and PHY906. RM and WE conducted the bioresponse gene expression fingerprints and quantitative PCR experiments. ZJ and SHL performed the animal pharmacology experiments. JB and HW developed the code and validated the PSI algorithm and implemented the PhytomicsQC platform software. ZP, AAP and RT conducted data analysis including PSI comparisons. YC developed the concept of phytomics and invented the bioresponse gene expression analysis. All authors read and approved the final version of the manuscript.
Chemical fingerprint of PHY906
We gratefully acknowledge the support of National Center for Complimentary and Alternative Medicine (NCCAM) and the Office of Dietary Supplements (ODS) (R44-AT001448) and the National Cancer Institute (NCI) (CA-63477) of the National Institute of Health USA and the National Foundation for Cancer Research. We also acknowledge that a small subset of the data and descriptions within this paper have been published in a recent clinical article, as a strict requirement to demonstrate quality control of PHY906 .